128
Participants
Start Date
December 12, 2018
Primary Completion Date
July 27, 2023
Study Completion Date
September 29, 2023
Biosimilar Infliximab
Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
Placebo
Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
Haukeland University Hospital, Bergen
Vestre Viken Hospital Trust Drammen, Drammen
Østfold Hospital Trust, Moss
University Hospital of North Norway, Tromsø
St. Olavs Hospital, Trondheim
Oslo University Hospital Ullevål, Oslo
Haukeland University Hospital
OTHER
St. Olavs Hospital
OTHER
University Hospital of North Norway
OTHER
Vestre Viken Hospital Trust
OTHER
Ostfold Hospital Trust
OTHER
Clinical Trial Unit (CTU), Oslo University Hospital
UNKNOWN
Diakonhjemmet Hospital
OTHER
Oslo University Hospital
OTHER